Entry Detail


General Information

Database ID:exR0095464
RNA Name:hsa-miR-1178-5p
RNA Type:miRNA
Chromosome:chr12
Starnd:-
Coordinate:
Start Site(bp):119713678End Site(bp):119713695
External Links:hsa-miR-1178-5p



Disease Information

Disease Name:Borderline Ovarian Tumor
Disease Category:Cancers
MeSH ID:D010051
Type:Neoplasms/Urogenital Neoplasms
Alias:Ovarian Neoplasms//Neoplasm, Ovarian//Ovarian Neoplasm//Ovary Neoplasms//Neoplasm, Ovary//Neoplasms, Ovary//Ovary Neoplasm//Neoplasms, Ovarian//Ovary Cancer//Cancer, Ovary//Cancers, Ovary//Ovary Cancers//Ovarian Cancer//Cancer, Ovarian//Cancers, Ovarian//Ovarian Cancers//Cancer of Ovary//Cancer of the Ovary



Expression Detail

GEO ID:GSE106817
Description:Integrated extracellular microRNA profiling for ovarian cancer screening
Experimental Design:Cancer vs Control
Case Disease Type:Benign Ovarian Disease
Case Disease SubType:NA
Case Sample:Borderline Ovarian Tumor
Control Sample:Non-Cancer
Number of Case:29
Number of Control:2759
Number of Samples:2788





Regulatory Relationship

mRNA targets:NA
miRNA targets:NA
circRNA targets:NA
lncRNA targets:NA
Display:N/A



Experiment Detail

GEO ID:GSE106817
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21263
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2535
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
RNA library preparation protocol:miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.



Reference

PMID:30333487
Title:Integrated extracellular microRNA profiling for ovarian cancer screening
Author:Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T
Journal:Nat Commun. 2018 Oct 17;9(1):4319.
Description:to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.